Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Fusion Pharmaceuticals (Nasdaq: FUSN) will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 2:40 PM ET, with CEO John Valliant, Ph.D. The presentation will be available via a live webcast on the Company's website, and a replay will be archived for 90 days after the event. Fusion is focused on developing next-generation radiopharmaceuticals, including its lead program FPI-1434 in a Phase 1 trial. The company has collaborations with AstraZeneca and Merck to enhance its innovative pipeline.
- None.
- None.
HAMILTON, ON and BOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 2:40pm ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2021-cantor-fitzgerald-virtual-global-healthcare-conference-301384279.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
What is Fusion Pharmaceuticals' upcoming presentation date?
Who will represent Fusion Pharmaceuticals at the conference?
How can I access the webcast of Fusion Pharmaceuticals' presentation?
What is the lead program of Fusion Pharmaceuticals?
What collaborations does Fusion Pharmaceuticals have?
